Apollomics Inc. Class A Ordinary Shares (APLM)vsBeOne Medicines AG (ONC)
APLM
Apollomics Inc. Class A Ordinary Shares
$17.50
-5.91%
HEALTHCARE · Cap: $60.31M
ONC
BeOne Medicines AG
$415.96
-0.96%
HEALTHCARE · Cap: $46.30B
Smart Verdict
WallStSmart Research — data-driven comparison
BeOne Medicines AG generates 74617% more annual revenue ($6.61B vs $8.84M). ONC leads profitability with a 13.9% profit margin vs -123.7%. ONC earns a higher WallStSmart Score of 70/100 (B-).
APLM
Avoid33
out of 100
Grade: F
ONC
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for APLM.
Margin of Safety
+81.0%
Fair Value
$1845.68
Current Price
$415.96
$1429.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 431.9%
Revenue surging 380.8% year-over-year
Conservative balance sheet, low leverage
Revenue surging 33.8% year-over-year
Earnings expanding 212.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 22.2%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1305.0% — below average capital efficiency
Trading at 8.2x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : APLM
The strongest argument for APLM centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 380.8% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : APLM
The primary concerns for APLM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 52.2x leaves little room for execution misses.
Key Dynamics to Monitor
APLM profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
APLM carries more volatility with a beta of 1.54 — expect wider price swings.
APLM is growing revenue faster at 380.8% — sustainability is the question.
ONC generates stronger free cash flow (474M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (70/100 vs 33/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apollomics Inc. Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Visit Website →BeOne Medicines AG
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?